Clinical-stage biotech Five Prime Therapeutics has a new bean counter.
The San Francisco-based novel protein developer announced today that Marc Belsky has taken on the role of chief financial officer, effective immediately. He has more than 30 years of finance and accounting experience, including seven in the biotech industry.
Before joining Five Prime in 2009, Belsky served as VP of finance and chief accounting officer of Cell Genesys, and before that he was VP, global Visa commerce, at Visa International , CFO at Active Aero Group, and CFO of DataWave Systems.
Noting that Belsky was instrumental in development of its financial operations and its IPO, Five Prime Therapeutics founder, President, and CEO Lewis T. Williams, said: "Marc has been an effective leader within Five Prime. His promotion to the role of Chief Financial Officer reflects our confidence in Marc's judgment and ability to improve our operations as we mature as a public company."
Belsky started his career as an auditor with Coopers & Lybrand and received a B.S. degree in accounting from Wayne State University and an M.B.A. from the University of Michigan. He is a CPA and a certified treasury professional.
Five Prime also announced that it appointed its senior VP and chief business officer, Aron Knickerbocker, to the company's board of directors. Knickerbocker has worked at the biotech since 2009 and has been in the biopharmaceutical industry for more than 20 years. Before joining Five Prime, Knickerbocker served as senior director of business development at Genentech.
The article Five Prime Therapeutics Gets a New CFO originally appeared on Fool.com.
Fool contributor Rich Duprey has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Visa. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.